BioXcel says independent audit of Alzheimer’s study found misconduct did not impact data reliability
BioXcel Therapeutics said Wednesday that it still plans to use data from a site in its Phase III Alzheimer’s disease study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.